Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enteral Phosphate Supplementation for Hypophosphatemia
NCT07233889Recruiting
- Start
- Nov 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Sodium phosphate monobasic monohydrate + sodium phosphate dibasic anhydrous in hypophosphatemia (3 arms). Primary endpoint: Rate of achieving target serum phosphorus levels at 14 days. Started Nov 2025; status: recruiting.
02
Drugs
Sodium phosphate monobasic monohydrate + sodium phosphate dibasic anhydrous
03
Conditions
hypophosphatemia
Beyond the preview
Go deeper on NCT07233889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233889.